Cargando…

Current Efavirenz (EFV) or Ritonavir-Boosted Lopinavir (LPV/r) Use Correlates with Elevate Markers of Atherosclerosis in HIV-Infected Subjects in Addis Ababa, Ethiopia

BACKGROUND: HIV patients on antiretroviral therapy have shown elevated incidence of dyslipidemia, lipodystrophy, and cardiovascular disease (CVD). Most studies, however, focus on cohorts from developed countries, with less data available for these co-morbidities in Ethiopia and sub-Saharan Africa. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Gleason, Rudolph L., Caulk, Alexander W., Seifu, Daniel, Parker, Ivana, Vidakovic, Brani, Getenet, Helena, Assefa, Getachew, Amogne, Wondwossen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411122/
https://www.ncbi.nlm.nih.gov/pubmed/25915208
http://dx.doi.org/10.1371/journal.pone.0117125
_version_ 1782368424186347520
author Gleason, Rudolph L.
Caulk, Alexander W.
Seifu, Daniel
Parker, Ivana
Vidakovic, Brani
Getenet, Helena
Assefa, Getachew
Amogne, Wondwossen
author_facet Gleason, Rudolph L.
Caulk, Alexander W.
Seifu, Daniel
Parker, Ivana
Vidakovic, Brani
Getenet, Helena
Assefa, Getachew
Amogne, Wondwossen
author_sort Gleason, Rudolph L.
collection PubMed
description BACKGROUND: HIV patients on antiretroviral therapy have shown elevated incidence of dyslipidemia, lipodystrophy, and cardiovascular disease (CVD). Most studies, however, focus on cohorts from developed countries, with less data available for these co-morbidities in Ethiopia and sub-Saharan Africa. METHODS: Adult HIV-negative (n = 36), treatment naïve (n = 51), efavirenz (EFV)-treated (n = 91), nevirapine (NVP)-treated (n = 95), or ritonavir-boosted lopinavir (LPV/r)-treated (n=44) subjects were recruited from Black Lion Hospital in Addis Ababa, Ethiopia. Aortic pressure, augmentation pressure, and pulse wave velocity (PWV) were measured via applanation tonometry and carotid intima-media thickness (cIMT) and carotid arterial stiffness, and brachial artery flow-mediated dilation (FMD) were measured via non-invasive ultrasound. Body mass index, waist-to-hip circumference ratio (WHR), skinfold thickness, and self-reported fat redistribution were used to quantify lipodystrophy. CD4+ cell count, plasma HIV RNA levels, fasting glucose, total-, HDL-, and LDL-cholesterol, triglycerides, hsCRP, sVCAM-1, sICAM-1, leptin and complete blood count were measured. RESULTS: PWV and normalized cIMT were elevate and FMD impaired in EFV- and LPV/r-treated subjects compared to NVP-treated subjects; normalized cIMT was also elevated and FMD impaired in the EFV- and LPV/r-treated subjects compared to treatment-naïve subjects. cIMT was not statistically different across groups. Treated subjects exhibited elevated markers of dyslipidemia, inflammation, and lipodystrophy. PWV was associated with age, current EFV and LPV/r used, heart rate, blood pressure, triglycerides, LDL, and hsCRP, FMD with age, HIV duration, WHR, and glucose, and cIMT with age, current EFV use, skinfold thickness, and blood pressure. CONCLUSIONS: Current EFV- or LPV/r-treatment, but not NVP-treatment, correlated with elevated markers of atherosclerosis, which may involve mechanisms distinct from traditional risk factors.
format Online
Article
Text
id pubmed-4411122
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-44111222015-05-07 Current Efavirenz (EFV) or Ritonavir-Boosted Lopinavir (LPV/r) Use Correlates with Elevate Markers of Atherosclerosis in HIV-Infected Subjects in Addis Ababa, Ethiopia Gleason, Rudolph L. Caulk, Alexander W. Seifu, Daniel Parker, Ivana Vidakovic, Brani Getenet, Helena Assefa, Getachew Amogne, Wondwossen PLoS One Research Article BACKGROUND: HIV patients on antiretroviral therapy have shown elevated incidence of dyslipidemia, lipodystrophy, and cardiovascular disease (CVD). Most studies, however, focus on cohorts from developed countries, with less data available for these co-morbidities in Ethiopia and sub-Saharan Africa. METHODS: Adult HIV-negative (n = 36), treatment naïve (n = 51), efavirenz (EFV)-treated (n = 91), nevirapine (NVP)-treated (n = 95), or ritonavir-boosted lopinavir (LPV/r)-treated (n=44) subjects were recruited from Black Lion Hospital in Addis Ababa, Ethiopia. Aortic pressure, augmentation pressure, and pulse wave velocity (PWV) were measured via applanation tonometry and carotid intima-media thickness (cIMT) and carotid arterial stiffness, and brachial artery flow-mediated dilation (FMD) were measured via non-invasive ultrasound. Body mass index, waist-to-hip circumference ratio (WHR), skinfold thickness, and self-reported fat redistribution were used to quantify lipodystrophy. CD4+ cell count, plasma HIV RNA levels, fasting glucose, total-, HDL-, and LDL-cholesterol, triglycerides, hsCRP, sVCAM-1, sICAM-1, leptin and complete blood count were measured. RESULTS: PWV and normalized cIMT were elevate and FMD impaired in EFV- and LPV/r-treated subjects compared to NVP-treated subjects; normalized cIMT was also elevated and FMD impaired in the EFV- and LPV/r-treated subjects compared to treatment-naïve subjects. cIMT was not statistically different across groups. Treated subjects exhibited elevated markers of dyslipidemia, inflammation, and lipodystrophy. PWV was associated with age, current EFV and LPV/r used, heart rate, blood pressure, triglycerides, LDL, and hsCRP, FMD with age, HIV duration, WHR, and glucose, and cIMT with age, current EFV use, skinfold thickness, and blood pressure. CONCLUSIONS: Current EFV- or LPV/r-treatment, but not NVP-treatment, correlated with elevated markers of atherosclerosis, which may involve mechanisms distinct from traditional risk factors. Public Library of Science 2015-04-27 /pmc/articles/PMC4411122/ /pubmed/25915208 http://dx.doi.org/10.1371/journal.pone.0117125 Text en © 2015 Gleason et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Gleason, Rudolph L.
Caulk, Alexander W.
Seifu, Daniel
Parker, Ivana
Vidakovic, Brani
Getenet, Helena
Assefa, Getachew
Amogne, Wondwossen
Current Efavirenz (EFV) or Ritonavir-Boosted Lopinavir (LPV/r) Use Correlates with Elevate Markers of Atherosclerosis in HIV-Infected Subjects in Addis Ababa, Ethiopia
title Current Efavirenz (EFV) or Ritonavir-Boosted Lopinavir (LPV/r) Use Correlates with Elevate Markers of Atherosclerosis in HIV-Infected Subjects in Addis Ababa, Ethiopia
title_full Current Efavirenz (EFV) or Ritonavir-Boosted Lopinavir (LPV/r) Use Correlates with Elevate Markers of Atherosclerosis in HIV-Infected Subjects in Addis Ababa, Ethiopia
title_fullStr Current Efavirenz (EFV) or Ritonavir-Boosted Lopinavir (LPV/r) Use Correlates with Elevate Markers of Atherosclerosis in HIV-Infected Subjects in Addis Ababa, Ethiopia
title_full_unstemmed Current Efavirenz (EFV) or Ritonavir-Boosted Lopinavir (LPV/r) Use Correlates with Elevate Markers of Atherosclerosis in HIV-Infected Subjects in Addis Ababa, Ethiopia
title_short Current Efavirenz (EFV) or Ritonavir-Boosted Lopinavir (LPV/r) Use Correlates with Elevate Markers of Atherosclerosis in HIV-Infected Subjects in Addis Ababa, Ethiopia
title_sort current efavirenz (efv) or ritonavir-boosted lopinavir (lpv/r) use correlates with elevate markers of atherosclerosis in hiv-infected subjects in addis ababa, ethiopia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411122/
https://www.ncbi.nlm.nih.gov/pubmed/25915208
http://dx.doi.org/10.1371/journal.pone.0117125
work_keys_str_mv AT gleasonrudolphl currentefavirenzefvorritonavirboostedlopinavirlpvrusecorrelateswithelevatemarkersofatherosclerosisinhivinfectedsubjectsinaddisababaethiopia
AT caulkalexanderw currentefavirenzefvorritonavirboostedlopinavirlpvrusecorrelateswithelevatemarkersofatherosclerosisinhivinfectedsubjectsinaddisababaethiopia
AT seifudaniel currentefavirenzefvorritonavirboostedlopinavirlpvrusecorrelateswithelevatemarkersofatherosclerosisinhivinfectedsubjectsinaddisababaethiopia
AT parkerivana currentefavirenzefvorritonavirboostedlopinavirlpvrusecorrelateswithelevatemarkersofatherosclerosisinhivinfectedsubjectsinaddisababaethiopia
AT vidakovicbrani currentefavirenzefvorritonavirboostedlopinavirlpvrusecorrelateswithelevatemarkersofatherosclerosisinhivinfectedsubjectsinaddisababaethiopia
AT getenethelena currentefavirenzefvorritonavirboostedlopinavirlpvrusecorrelateswithelevatemarkersofatherosclerosisinhivinfectedsubjectsinaddisababaethiopia
AT assefagetachew currentefavirenzefvorritonavirboostedlopinavirlpvrusecorrelateswithelevatemarkersofatherosclerosisinhivinfectedsubjectsinaddisababaethiopia
AT amognewondwossen currentefavirenzefvorritonavirboostedlopinavirlpvrusecorrelateswithelevatemarkersofatherosclerosisinhivinfectedsubjectsinaddisababaethiopia